| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
Cinvanti is owned by Heron Theraps Inc.
Cinvanti contains Aprepitant.
Cinvanti has a total of 9 drug patents out of which 0 drug patents have expired.
Cinvanti was authorised for market use on 09 November, 2017.
Cinvanti is available in emulsion;intravenous dosage forms.
Cinvanti can be used as treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy.
The generics of Cinvanti are possible to be released after 18 September, 2035.
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 09 November, 2017
Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy
Dosage: EMULSION;INTRAVENOUS
CINVANTI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic